SG11201608701QA - Crispr-cas-related methods, compositions and components for cancer immunotherapy - Google Patents

Crispr-cas-related methods, compositions and components for cancer immunotherapy

Info

Publication number
SG11201608701QA
SG11201608701QA SG11201608701QA SG11201608701QA SG11201608701QA SG 11201608701Q A SG11201608701Q A SG 11201608701QA SG 11201608701Q A SG11201608701Q A SG 11201608701QA SG 11201608701Q A SG11201608701Q A SG 11201608701QA SG 11201608701Q A SG11201608701Q A SG 11201608701QA
Authority
SG
Singapore
Prior art keywords
crispr
cas
compositions
components
related methods
Prior art date
Application number
SG11201608701QA
Inventor
G Grant Welstead
Ari E Friedland
Morgan L Maeder
David A Bumcrot
Original Assignee
Editas Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Editas Medicine Inc filed Critical Editas Medicine Inc
Publication of SG11201608701QA publication Critical patent/SG11201608701QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/55—Vector systems having a special element relevant for transcription from bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201608701QA 2014-04-18 2015-04-17 Crispr-cas-related methods, compositions and components for cancer immunotherapy SG11201608701QA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461981636P 2014-04-18 2014-04-18
US201562138246P 2015-03-25 2015-03-25
PCT/US2015/026504 WO2015161276A2 (en) 2014-04-18 2015-04-17 Crispr-cas-related methods, compositions and components for cancer immunotherapy

Publications (1)

Publication Number Publication Date
SG11201608701QA true SG11201608701QA (en) 2016-11-29

Family

ID=53059426

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201809157VA SG10201809157VA (en) 2014-04-18 2015-04-17 Crispr-cas-related methods, compositions and components for cancer immunotherapy
SG10201912171PA SG10201912171PA (en) 2014-04-18 2015-04-17 Crispr-cas-related methods, compositions and components for cancer immunotherapy
SG11201608701QA SG11201608701QA (en) 2014-04-18 2015-04-17 Crispr-cas-related methods, compositions and components for cancer immunotherapy

Family Applications Before (2)

Application Number Title Priority Date Filing Date
SG10201809157VA SG10201809157VA (en) 2014-04-18 2015-04-17 Crispr-cas-related methods, compositions and components for cancer immunotherapy
SG10201912171PA SG10201912171PA (en) 2014-04-18 2015-04-17 Crispr-cas-related methods, compositions and components for cancer immunotherapy

Country Status (10)

Country Link
US (2) US20170175128A1 (en)
EP (2) EP3132030B1 (en)
JP (3) JP2017513485A (en)
KR (2) KR20230152175A (en)
CN (1) CN108138183A (en)
AU (1) AU2015247323B2 (en)
CA (1) CA2945335A1 (en)
IL (4) IL292512B2 (en)
SG (3) SG10201809157VA (en)
WO (1) WO2015161276A2 (en)

Families Citing this family (176)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013066438A2 (en) 2011-07-22 2013-05-10 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
JP6219832B2 (en) 2011-10-17 2017-10-25 マサチューセッツ インスティテュート オブ テクノロジー Intracellular delivery
EP2841572B1 (en) 2012-04-27 2019-06-19 Duke University Genetic correction of mutated genes
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
AU2014306423B2 (en) 2013-08-16 2019-04-18 Massachusetts Institute Of Technology Selective delivery of material to cells
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
PT3066201T (en) 2013-11-07 2018-06-04 Massachusetts Inst Technology Crispr-related methods and compositions with governing grnas
US11053481B2 (en) 2013-12-12 2021-07-06 President And Fellows Of Harvard College Fusions of Cas9 domains and nucleic acid-editing domains
MA40253A (en) 2014-07-15 2017-05-24 Juno Therapeutics Inc Engineered cells for adoptive cell therapy
AU2015298571B2 (en) 2014-07-30 2020-09-03 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
KR20170074235A (en) 2014-10-31 2017-06-29 메사추세츠 인스티튜트 오브 테크놀로지 Delivery of biomolecules to immune cells
US20170335331A1 (en) 2014-10-31 2017-11-23 The Trustees Of The University Of Pennsylvania Altering Gene Expression in CART Cells and Uses Thereof
CN113897285A (en) 2014-11-14 2022-01-07 麻省理工学院 Disruption and field-effected delivery of compounds and compositions into cells
WO2016094867A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Protected guide rnas (pgrnas)
WO2016094874A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Escorted and functionalized guides for crispr-cas systems
WO2016094880A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Delivery, use and therapeutic applications of crispr systems and compositions for genome editing as to hematopoietic stem cells (hscs)
CA2970370A1 (en) 2014-12-24 2016-06-30 Massachusetts Institute Of Technology Crispr having or associated with destabilization domains
US11125739B2 (en) 2015-01-12 2021-09-21 Massachusetts Institute Of Technology Gene editing through microfluidic delivery
WO2016154596A1 (en) * 2015-03-25 2016-09-29 Editas Medicine, Inc. Crispr/cas-related methods, compositions and components
MX2017012407A (en) * 2015-03-27 2018-03-07 Harvard College Modified t cells and methods of making and using the same.
US10968426B2 (en) 2015-05-08 2021-04-06 President And Fellows Of Harvard College Universal donor stem cells and related methods
CA2986310A1 (en) * 2015-05-11 2016-11-17 Editas Medicine, Inc. Optimized crispr/cas9 systems and methods for gene editing in stem cells
AU2016262521A1 (en) * 2015-05-11 2017-12-14 Editas Medicine, Inc. CRISPR/CAS-related methods and compositions for treating HIV infection and AIDS
JP6949728B2 (en) 2015-05-29 2021-10-13 ジュノー セラピューティクス インコーポレイテッド Compositions and Methods for Modulating Inhibitory Interactions in Genetically Engineered Cells
AU2016276702B2 (en) 2015-06-09 2022-07-28 Editas Medicine, Inc. CRISPR/CAS-related methods and compositions for improving transplantation
AU2016279062A1 (en) 2015-06-18 2019-03-28 Omar O. Abudayyeh Novel CRISPR enzymes and systems
CA2988996A1 (en) 2015-07-09 2017-01-12 Massachusetts Institute Of Technology Delivery of materials to anucleate cells
MA42895A (en) 2015-07-15 2018-05-23 Juno Therapeutics Inc MODIFIED CELLS FOR ADOPTIVE CELL THERAPY
US10906951B2 (en) 2015-07-29 2021-02-02 Onk Therapeutics Limited Modified natural killer cells and natural killer cell lines having increased cytotoxicity
AU2016300128B2 (en) 2015-07-29 2022-03-17 Onk Therapeutics Limited Modified natural killer cells and natural killer cell lines having increased cytotoxicity
WO2017023803A1 (en) 2015-07-31 2017-02-09 Regents Of The University Of Minnesota Modified cells and methods of therapy
EP3344575B1 (en) 2015-09-04 2020-04-15 SQZ Biotechnologies Company Intracellular delivery of biomolecules to cells comprising a cell wall
EP3362571A4 (en) 2015-10-13 2019-07-10 Duke University Genome engineering with type i crispr systems in eukaryotic cells
JP7109784B2 (en) 2015-10-23 2022-08-01 プレジデント アンド フェローズ オブ ハーバード カレッジ Evolved Cas9 protein for gene editing
CN109312338B (en) 2015-10-30 2022-09-27 爱迪塔斯医药公司 CRISPR/CAS related methods and compositions for treating herpes simplex virus
CN108699557A (en) * 2015-12-04 2018-10-23 诺华股份有限公司 Composition for oncology to be immunized and method
CN108779475A (en) * 2016-01-12 2018-11-09 Sqz生物技术公司 The Intracellular delivery of compound
US11530253B2 (en) 2016-02-25 2022-12-20 The Children's Medical Center Corporation Customized class switch of immunoglobulin genes in lymphoma and hybridoma by CRISPR/CAS9 technology
MX2018010484A (en) * 2016-03-04 2019-01-10 Editas Medicine Inc Crispr-cpf1-related methods, compositions and components for cancer immunotherapy.
EP3219799A1 (en) 2016-03-17 2017-09-20 IMBA-Institut für Molekulare Biotechnologie GmbH Conditional crispr sgrna expression
KR20190080825A (en) * 2016-03-21 2019-07-08 다나-파버 캔서 인스티튜트 인크. T-cell dysfunction state-specific gene expression regulators and their uses
EP3445375A1 (en) * 2016-04-22 2019-02-27 Intellia Therapeutics, Inc. Compositions and methods for treatment of diseases associated with trinucleotide repeats in transcription factor four
CN107304434A (en) * 2016-04-25 2017-10-31 上海宇玫博生物科技有限公司 A kind of difunctional novel carriers of immune cell therapy
CN116850305A (en) * 2016-05-06 2023-10-10 朱诺治疗学股份有限公司 Genetically engineered cells and methods of making same
EP3452055A4 (en) * 2016-05-06 2019-11-06 Tod M. Woolf Improved methods for genome editing with and without programmable nucleases
DK3476865T3 (en) 2016-06-28 2023-12-18 Biocytogen Pharmaceuticals Beijing Co Ltd PROCEDURE FOR CONSTRUCTION OF PD-1 GENE-MODIFIED HUMANIZED ANIMAL MODEL AND USE THEREOF
US11078481B1 (en) 2016-08-03 2021-08-03 KSQ Therapeutics, Inc. Methods for screening for cancer targets
CN110214183A (en) 2016-08-03 2019-09-06 哈佛大学的校长及成员们 Adenosine nucleobase editing machine and application thereof
EP3494132A4 (en) * 2016-08-03 2020-03-18 Washington University Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors
US11661590B2 (en) 2016-08-09 2023-05-30 President And Fellows Of Harvard College Programmable CAS9-recombinase fusion proteins and uses thereof
WO2018035388A1 (en) 2016-08-17 2018-02-22 The Broad Institute, Inc. Novel crispr enzymes and systems
CA3033788A1 (en) 2016-08-17 2018-02-22 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
US11078483B1 (en) 2016-09-02 2021-08-03 KSQ Therapeutics, Inc. Methods for measuring and improving CRISPR reagent function
CN110139873A (en) 2016-10-03 2019-08-16 朱诺治疗学股份有限公司 HPV specific binding molecules
EP4190335A1 (en) 2016-10-13 2023-06-07 Juno Therapeutics, Inc. Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators
SG11201903089RA (en) 2016-10-14 2019-05-30 Harvard College Aav delivery of nucleobase editors
JP7181862B2 (en) 2016-10-18 2022-12-01 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ Tumor-infiltrating lymphocytes and methods of treatment
AU2017347848A1 (en) * 2016-10-27 2019-05-23 Intima Bioscience, Inc. Viral methods of making genetically modified cells
US11332713B2 (en) 2016-11-16 2022-05-17 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
EP3546577B1 (en) 2016-11-28 2021-11-17 Napajen Pharma, Inc. Chemically-modified sirna
MA46998A (en) 2016-12-05 2019-10-09 Juno Therapeutics Inc PRODUCTION OF MODIFIED CELLS FOR ADOPTIVE CELL THERAPY
CN110191955B (en) 2016-12-13 2024-05-31 西雅图儿童医院（Dba西雅图儿童研究所） Method for exogenous drug activation of chemical-induced signaling complexes expressed in engineered cells in vitro and in vivo
US10745677B2 (en) 2016-12-23 2020-08-18 President And Fellows Of Harvard College Editing of CCR5 receptor gene to protect against HIV infection
CN110913870A (en) * 2016-12-30 2020-03-24 细胞结构公司 Genetically modified natural killer cells
CN110520156A (en) * 2017-01-29 2019-11-29 唐泽群 For the immunoregulation method of exogenous antigen and/or autoantigen
TW201839136A (en) 2017-02-06 2018-11-01 瑞士商諾華公司 Compositions and methods for the treatment of hemoglobinopathies
US10828330B2 (en) * 2017-02-22 2020-11-10 IO Bioscience, Inc. Nucleic acid constructs comprising gene editing multi-sites and uses thereof
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
JP2020510439A (en) 2017-03-10 2020-04-09 プレジデント アンド フェローズ オブ ハーバード カレッジ Base-editing factor from cytosine to guanine
WO2018175636A2 (en) * 2017-03-22 2018-09-27 Novartis Ag Compositions and methods for immunooncology
IL306092A (en) 2017-03-23 2023-11-01 Harvard College Nucleobase editors comprising nucleic acid programmable dna binding proteins
WO2018191490A1 (en) * 2017-04-13 2018-10-18 The Trustees Of The University Of Pennsylvania Use of gene editing to generate universal tcr re-directed t cells for adoptive immunotherapy
WO2018209320A1 (en) 2017-05-12 2018-11-15 President And Fellows Of Harvard College Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
US11166985B2 (en) 2017-05-12 2021-11-09 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
AU2018367896B2 (en) 2017-05-12 2023-06-01 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
EP3635104A1 (en) 2017-06-09 2020-04-15 Editas Medicine, Inc. Engineered cas9 nucleases
KR20200018645A (en) 2017-06-15 2020-02-19 더 리전트 오브 더 유니버시티 오브 캘리포니아 Targeted non-viral DNA insertion
CA3064807A1 (en) * 2017-06-20 2018-12-27 Jiangsu Hengrui Medicine Co., Ltd. Method for knocking out target gene in t cell in vitro and crrna used in the method
SG10201705285SA (en) * 2017-06-27 2019-01-30 Agency Science Tech & Res Antisense oligonucleotides
US20200140896A1 (en) * 2017-06-30 2020-05-07 Novartis Ag Methods for the treatment of disease with gene editing systems
WO2019006418A2 (en) 2017-06-30 2019-01-03 Intima Bioscience, Inc. Adeno-associated viral vectors for gene therapy
EP3658573A1 (en) 2017-07-28 2020-06-03 President and Fellows of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace)
EP3676376A2 (en) 2017-08-30 2020-07-08 President and Fellows of Harvard College High efficiency base editors comprising gam
CN111148533A (en) 2017-09-19 2020-05-12 麻省理工学院 Compositions for chimeric antigen receptor T cell therapy and uses thereof
KR20200104284A (en) 2017-10-03 2020-09-03 주노 쎄러퓨티크스 인코퍼레이티드 HPV-specific binding molecule
WO2019072241A1 (en) 2017-10-13 2019-04-18 Beijing Biocytogen Co., Ltd Genetically modified non-human animal with human or chimeric pd-1
CN111757937A (en) 2017-10-16 2020-10-09 布罗德研究所股份有限公司 Use of adenosine base editor
IL274179B2 (en) 2017-10-27 2024-02-01 Univ California Targeted replacement of endogenous t cell receptors
WO2019089982A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Method of assessing activity of recombinant antigen receptors
JP2021502077A (en) * 2017-11-06 2021-01-28 エディタス・メディシン，インコーポレイテッド Methods, compositions and components for CRISPR-CAS9 editing of CBLB on T cells for immunotherapy
CN111655292A (en) * 2017-12-07 2020-09-11 旗舰先锋创新V股份有限公司 Cellular biologicals and therapeutic uses thereof
WO2019118508A1 (en) 2017-12-12 2019-06-20 The Trustees Of The University Of Pennsylvania Genetically modified immune cells targeting ny-eso-1 and methods of use thereof
WO2019118793A2 (en) * 2017-12-14 2019-06-20 Ezy Biotech Llc Subject-specific tumor inhibiting cells and the use thereof
DK3765615T3 (en) 2018-03-14 2023-08-21 Arbor Biotechnologies Inc NEW ENZYMES AND SYSTEMS FOR TARGETING CRISPR DNA
EP3765094A4 (en) 2018-03-15 2021-12-22 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
CA3093915A1 (en) 2018-03-15 2019-09-19 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
RU2020136054A (en) 2018-04-05 2022-05-06 Джуно Терапьютикс, Инк. T-CELLS EXPRESSING RECOMBINANT RECEPTOR, CORRESPONDING POLYNUCLEOTIDES AND METHODS
CN112566698A (en) 2018-04-05 2021-03-26 朱诺治疗学股份有限公司 T cell receptor and engineered cells expressing the same
BR112020020245A2 (en) 2018-04-05 2021-04-06 Editas Medicine, Inc. METHODS OF PRODUCING CELLS EXPRESSING A RECOMBINANT RECEIVER AND RELATED COMPOSITIONS
CN112384621A (en) * 2018-04-13 2021-02-19 西格马-奥尔德里奇有限责任公司 Modification of immune-related genomic loci using paired CRISPR nickase ribonucleoproteins
KR20210016353A (en) 2018-04-27 2021-02-15 시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 Rapamycin-resistant cells
BR112020022879A2 (en) 2018-05-11 2021-02-23 Crispr Therapeutics Ag methods and compositions for cancer treatment
CN108866004A (en) * 2018-06-26 2018-11-23 奥妙生物技术（广州）有限公司 The T cell and its construction method that SHP-1 is knocked out
CN112823011A (en) * 2018-07-09 2021-05-18 加利福尼亚大学董事会 Gene targets for T cell-based immunotherapy
WO2020022802A1 (en) * 2018-07-25 2020-01-30 주식회사 툴젠 Genome editing for treating autoimmune disease
WO2020022803A1 (en) * 2018-07-26 2020-01-30 주식회사 툴젠 Gene editing of anticoagulants
WO2020051283A1 (en) 2018-09-05 2020-03-12 The Regents Of The University Of California Generation of heritably gene-edited plants without tissue culture
EP3849305B1 (en) * 2018-09-11 2023-12-13 Board of Regents, The University of Texas System A genetic mouse model of autoimmune adverse events and immune checkpoint blockade therapy
JP2022502037A (en) 2018-09-28 2022-01-11 マサチューセッツ インスティテュート オブ テクノロジー Immunomodulatory molecules localized to collagen and their methods
WO2020072059A1 (en) * 2018-10-04 2020-04-09 Bluebird Bio, Inc. Cblb endonuclease variants, compositions, and methods of use
BR112021007025A2 (en) * 2018-10-16 2021-08-03 Intellia Therapeutics, Inc. compositions and methods for immunotherapy
AU2019372642B2 (en) * 2018-10-29 2023-11-23 China Agricultural University Novel CRISPR/Cas12f enzyme and system
CN113544266A (en) 2018-12-17 2021-10-22 博德研究所 CRISPR-associated transposase systems and methods of use thereof
WO2020157750A1 (en) * 2019-01-28 2020-08-06 Bar Ilan University Combinations, nanoparticles and methods for controlling natural killer cell activation and function
MX2021009742A (en) 2019-02-15 2021-12-10 Editas Medicine Inc Modified natural killer (nk) cells for immunotherapy.
WO2020191241A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
CN113966401A (en) 2019-04-10 2022-01-21 犹他大学研究基金会 HTRA1 modulation for the treatment of AMD
US20220249558A1 (en) 2019-04-30 2022-08-11 Crispr Therapeutics Ag Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19
CA3136742A1 (en) 2019-05-01 2020-11-05 Juno Therapeutics, Inc. Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods
MX2021013219A (en) 2019-05-01 2022-02-17 Juno Therapeutics Inc Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods.
US20220235340A1 (en) 2019-05-20 2022-07-28 The Broad Institute, Inc. Novel crispr-cas systems and uses thereof
CN114206936A (en) * 2019-06-14 2022-03-18 2赛文缇生物公司 Compositions and methods for treating cancer
EP3990491A1 (en) 2019-06-26 2022-05-04 Massachusetts Institute of Technology Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
WO2021041922A1 (en) 2019-08-30 2021-03-04 The Broad Institute, Inc. Crispr-associated mu transposase systems
WO2021061648A1 (en) 2019-09-23 2021-04-01 Massachusetts Institute Of Technology Methods and compositions for stimulation of endogenous t cell responses
WO2021150078A1 (en) * 2020-01-23 2021-07-29 주식회사 강스템바이오텍 Off-the-shelf stem cells and immune cells, and pharmaceutical composition comprising same
CN115485295A (en) 2020-03-10 2022-12-16 麻省理工学院 Compositions and methods for immunotherapy of NPM1 c-positive cancers
WO2021216622A1 (en) 2020-04-21 2021-10-28 Aspen Neuroscience, Inc. Gene editing of gba1 in stem cells and method of use of cells differentiated therefrom
WO2021216623A1 (en) 2020-04-21 2021-10-28 Aspen Neuroscience, Inc. Gene editing of lrrk2 in stem cells and method of use of cells differentiated therefrom
WO2021221782A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Chimeric antigen receptor-targeting ligands and uses thereof
WO2021221783A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
CA3177481A1 (en) 2020-05-08 2021-11-11 David R. Liu Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
EP4150057A2 (en) 2020-05-13 2023-03-22 Juno Therapeutics, Inc. Process for producing donor-batched cells expressing a recombinant receptor
CA3178670A1 (en) * 2020-06-03 2021-12-09 Lucas Benjamin HARRINGTON Programmable nucleases and methods of use
US20240216508A1 (en) 2020-06-26 2024-07-04 Juno Therapeutics Gmbh Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods
US11332744B1 (en) 2020-10-26 2022-05-17 Arsenal Biosciences, Inc. Safe harbor loci
US20230398148A1 (en) 2020-11-04 2023-12-14 Juno Therapeutics, Inc. Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods
GB2617799A (en) * 2021-02-01 2023-10-18 Epsilen Bio S R L Gene silencing
CN117693508A (en) 2021-03-03 2024-03-12 朱诺治疗学股份有限公司 Combination of T cell therapy and DGK inhibitors
CA3208944A1 (en) 2021-03-22 2022-09-29 Edith NALBANDIAN Method to assess potency of viral vector particles
WO2022215982A1 (en) * 2021-04-05 2022-10-13 주식회사 셀렌진 Guide rna complementary to trac gene and use thereof
WO2022232839A1 (en) 2021-04-30 2022-11-03 The Board Of Trustees Of The Leland Stanford Junior University Methods for improved production of primary cd34+ cells
US20230016422A1 (en) * 2021-06-23 2023-01-19 Crispr Therapeutics Ag Engineered cells with improved protection from natural killer cell killing
AU2022301302A1 (en) 2021-07-01 2024-01-25 Indapta Therapeutics, Inc. Engineered natural killer (nk) cells and related methods
AU2022318664A1 (en) 2021-07-30 2024-02-29 Tune Therapeutics, Inc. Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2)
WO2023010133A2 (en) 2021-07-30 2023-02-02 Tune Therapeutics, Inc. Compositions and methods for modulating expression of frataxin (fxn)
KR20240099259A (en) 2021-10-14 2024-06-28 아스널 바이오사이언시스, 인크. Immune cells with co-expressed SHRNA and logic gate system
WO2023077149A1 (en) 2021-11-01 2023-05-04 Sigma-Aldrich Co. Llc Electroporation enhancers for crispr-cas systems
WO2023081715A1 (en) 2021-11-03 2023-05-11 Viracta Therapeutics, Inc. Combination of car t-cell therapy with btk inhibitors and methods of use thereof
WO2023081900A1 (en) 2021-11-08 2023-05-11 Juno Therapeutics, Inc. Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
TW202342498A (en) 2021-12-17 2023-11-01 美商薩那生物科技公司 Modified paramyxoviridae fusion glycoproteins
WO2023115041A1 (en) 2021-12-17 2023-06-22 Sana Biotechnology, Inc. Modified paramyxoviridae attachment glycoproteins
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023137472A2 (en) 2022-01-14 2023-07-20 Tune Therapeutics, Inc. Compositions, systems, and methods for programming t cell phenotypes through targeted gene repression
WO2023137471A1 (en) 2022-01-14 2023-07-20 Tune Therapeutics, Inc. Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation
WO2023150518A1 (en) 2022-02-01 2023-08-10 Sana Biotechnology, Inc. Cd3-targeted lentiviral vectors and uses thereof
WO2023150647A1 (en) 2022-02-02 2023-08-10 Sana Biotechnology, Inc. Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023201133A1 (en) 2022-04-14 2023-10-19 Board Of Regents Of The University Of Nebraska Cell therapy for alzheimer's disease
WO2023224715A1 (en) 2022-05-19 2023-11-23 Massachusetts Institute Of Technology Car cells targeting an inserted ligand
WO2023250511A2 (en) 2022-06-24 2023-12-28 Tune Therapeutics, Inc. Compositions, systems, and methods for reducing low-density lipoprotein through targeted gene repression
WO2024007020A1 (en) 2022-06-30 2024-01-04 Indapta Therapeutics, Inc. Combination of engineered natural killer (nk) cells and antibody therapy and related methods
WO2024015881A2 (en) 2022-07-12 2024-01-18 Tune Therapeutics, Inc. Compositions, systems, and methods for targeted transcriptional activation
US20240067969A1 (en) 2022-08-19 2024-02-29 Tune Therapeutics, Inc. Compositions, systems, and methods for regulation of hepatitis b virus through targeted gene repression
WO2024044655A1 (en) 2022-08-24 2024-02-29 Sana Biotechnology, Inc. Delivery of heterologous proteins
WO2024054944A1 (en) 2022-09-08 2024-03-14 Juno Therapeutics, Inc. Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing
WO2024064642A2 (en) 2022-09-19 2024-03-28 Tune Therapeutics, Inc. Compositions, systems, and methods for modulating t cell function
WO2024064606A2 (en) * 2022-09-19 2024-03-28 Emendobio Inc. Biallelic knockout of ctla4
WO2024064838A1 (en) 2022-09-21 2024-03-28 Sana Biotechnology, Inc. Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
WO2024081820A1 (en) 2022-10-13 2024-04-18 Sana Biotechnology, Inc. Viral particles targeting hematopoietic stem cells
WO2024100604A1 (en) 2022-11-09 2024-05-16 Juno Therapeutics Gmbh Methods for manufacturing engineered immune cells
WO2024119157A1 (en) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same
CN116539885B (en) * 2023-07-06 2023-09-29 上海秤信生物科技有限公司 Tumor autoantigen/antibody combination for early detection of breast cancer and application thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3362867B2 (en) * 1991-04-26 2003-01-07 財団法人大阪バイオサイエンス研究所 DNA encoding human cell surface antigen
GEP20217251B (en) * 2012-05-25 2021-04-26 Charpentier Emmanuelle De Emanuel Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
EP3276000A3 (en) * 2012-05-25 2018-02-21 Cellectis Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
ES2824024T3 (en) * 2012-10-10 2021-05-11 Sangamo Therapeutics Inc T cell modifying compounds and uses thereof
US8697359B1 (en) * 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
AU2014235968B2 (en) * 2013-03-21 2018-05-24 Ospedale San Raffaele Srl Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
CA2912375C (en) * 2013-05-13 2023-03-14 Cellectis Methods for engineering highly active t cell for immunotherapy
DK3309248T3 (en) * 2013-05-29 2021-08-02 Cellectis Method for manipulating T cells for immunotherapy using an RNA-guided CAS nuclease system
DK3011031T3 (en) * 2013-06-17 2020-12-21 Broad Inst Inc PERFORMANCE AND APPLICATION OF CRISPR-CAS SYSTEMS, VECTORS AND COMPOSITIONS FOR LIVER TARGET DIRECTION AND THERAPY
JP6681837B2 (en) * 2014-03-11 2020-04-15 セレクティスＣｅｌｌｅｃｔｉｓ Method for making T cells compatible with allogeneic transplantation
WO2016154596A1 (en) * 2015-03-25 2016-09-29 Editas Medicine, Inc. Crispr/cas-related methods, compositions and components

Also Published As

Publication number Publication date
IL292512B2 (en) 2024-07-01
IL292512B1 (en) 2024-03-01
KR20230152175A (en) 2023-11-02
JP2017513485A (en) 2017-06-01
SG10201912171PA (en) 2020-02-27
KR20170009865A (en) 2017-01-25
CA2945335A1 (en) 2015-10-22
EP3132030B1 (en) 2020-08-26
US20220106600A1 (en) 2022-04-07
WO2015161276A3 (en) 2015-12-10
IL292512A (en) 2022-06-01
IL286103B (en) 2022-06-01
SG10201809157VA (en) 2018-11-29
IL248284A0 (en) 2016-11-30
EP3800248A3 (en) 2021-08-04
IL286103A (en) 2021-10-31
CN108138183A (en) 2018-06-08
JP2020062029A (en) 2020-04-23
KR102595473B1 (en) 2023-10-30
JP2024073596A (en) 2024-05-29
WO2015161276A2 (en) 2015-10-22
EP3800248A2 (en) 2021-04-07
AU2015247323A1 (en) 2016-11-10
IL279230A (en) 2021-01-31
US20170175128A1 (en) 2017-06-22
IL279230B (en) 2021-09-30
EP3132030A2 (en) 2017-02-22
JP2022081522A (en) 2022-05-31
AU2015247323B2 (en) 2021-07-01

Similar Documents

Publication Publication Date Title
IL286103B (en) Crispr-cas-related methods, compositions and components for cancer immunotherapy
IL261163B (en) Crispr-cpf1-related methods, compositions and components for cancer immunotherapy
IL286025A (en) Nanoparticle compositions and methods for immunotherapy
HK1246319A1 (en) Combination tumor immunotherapy
IL253341A0 (en) Methods and compositions for combination immunotherapy
IL246681A0 (en) Compounds and compositions for immunotherapy
IL264454A (en) Novel compositions, uses and methods for making them
IL248235B (en) Method and compositions for cellular immunotherapy
EP3286213A4 (en) Methods and compositions for combination immunotherapy
EP3200815A4 (en) Methods and compositions for treating cancer
EP3247408A4 (en) Compositions and methods for cancer immunotherapy
EP3154544A4 (en) Compositions and methods for treating cancers
AU2021236446A1 (en) CRISPR-Cas-related methods, compositions and components for cancer immunotherapy
EP3160591A4 (en) Compositions and methods for treating cancer
AU2014902028A0 (en) Cancer immunotherapy